NCT06149104View on ClinicalTrials.gov

A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study

PHASE3CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 4, 2023

Primary Completion Date

August 14, 2024

Study Completion Date

August 14, 2024

Conditions
Heart Failure
Interventions
DRUG

sacubitril/valsartan

sacubiril/valsartan

Trial Locations (6)

474 8710

Novartis Investigative Site, Ōbu

856-8562

Novartis Investigative Site, Ōmura

113 8655

Novartis Investigative Site, Bunkyo Ku

157-8535

Novartis Investigative Site, Setagaya-ku

330 8777

Novartis Investigative Site, Saitama

930-0194

Novartis Investigative Site, Toyama

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY